Goldman Sachs
BLCM

Goldman Sachs’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Goldman Sachs’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,305
Closed -$14K – 5463
2019
Q3 		$14K Sell
1,305
-65,958
-98% -$862K ﹤0.01% 5119
2019
Q2 		$1.14M Buy
67,263
+51,885
+337% +$1.4M ﹤0.01% 3905
2019
Q1 		$518K Sell
15,378
-5,188
-25% -$173K ﹤0.01% 4406
2018
Q4 		$600K Sell
20,566
-2,327
-10% -$103K ﹤0.01% 4253
2018
Q3 		$1.41M Sell
22,893
-3,333
-13% -$226K ﹤0.01% 3828
2018
Q2 		$1.94M Buy
26,226
+9,378
+56% +$731K ﹤0.01% 3645
2018
Q1 		$1.1M Buy
16,848
+1,962
+13% +$148K ﹤0.01% 3991
2017
Q4 		$1.25M Buy
14,886
+1,926
+15% +$189K ﹤0.01% 4161
2017
Q3 		$1.5M Sell
12,960
-840
-6% -$88.4K ﹤0.01% 4231
2017
Q2 		$1.61M Buy
13,800
+9,534
+223% +$1.18M ﹤0.01% 4009
2017
Q1 		$526K Buy
4,266
+1,386
+48% +$182K ﹤0.01% 4985
2016
Q4 		$392K Buy
2,880
+1,638
+132% +$291K ﹤0.01% 5271
2016
Q3 		$247K Sell
1,242
-4,864
-80% -$838K ﹤0.01% 5639
2016
Q2 		$791K Buy
+6,106
New +$680K ﹤0.01% 4411
2016
Q1 		– Sell
-7,722
Closed -$1.56M – 7392
2015
Q4 		$1.56M Buy
+7,722
New +$1.38M ﹤0.01% 3850
2015
Q2 		– Sell
-1,456
Closed -$337K – 7493
2015
Q1 		$337K Sell
1,456
-2,219
-60% -$537K ﹤0.01% 5532
2014
Q4 		$847K Buy
+3,675
New +$788K ﹤0.01% 4755

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's BLCM Position: Q4 2019 in Review

Goldman Sachs sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2019, closing a stake of 1,305 shares — an estimated $14K sold.

Goldman Sachs first reported a position in BLCM in Q4 2014 and held it in 17 quarters. The position peaked at $1.94M in Q2 2018. 51 funds tracked by Wall St. Rank hold BLCM as of Q4 2019.

  • Goldman Sachs reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Goldman Sachs sold 1,305 Bellicum Pharmaceuticals, Inc. shares in Q4 2019, an estimated $14K.
  • Goldman Sachs first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 17 quarters.
  • Goldman Sachs's Bellicum Pharmaceuticals, Inc. position peaked at $1.94M in Q2 2018.
  • 51 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2019.

Based on Goldman Sachs's 13F filing for Q4 2019, filed 14 Feb 2020.